TG Therapeutics Inc (TGTX)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 33% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+47% over the past year+3
- 52-week positionAbove the midpoint of its 52-week range+9
- QualityRevenue growing 76% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is macro, since TGTX's recent headlines are sector- and rate-driven rather than company-specific news like earnings, product data, or M&A. Continuation likelihood over the next few weeks is modest and uncertain, as biotech moves tied to interest-rate sentiment and broad market risk appetite tend to be choppy rather than persistent. Informational only — not financial advice.
- Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts ApproachBenzinga · 2026-09-25
- Novo Nordisk: Capital Markets Day Reveals Its Next Growth EngineSeekingAlpha · 2026-09-24
- Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy SignalsYahoo · 2026-09-23
- Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy SignalsYahoo · 2026-09-23
- TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth With a Tight Technical Breakout SetupChartMill · 2026-09-21
Any AI summary is an interpretation of public news, not advice or a price target.